Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06RUK
|
|||
Former ID |
DIB013138
|
|||
Drug Name |
Combotox
|
|||
Synonyms |
IMTOX 22; Anti CD22/N97A; Anti CD22/ricin; Anti CD19 + anti CD22/N97A; Ricin-conjugated anti-CD22 and anti-CD19; IgG-RFB4-dgA and IgG-HD37-dgA
Click to Show/Hide
|
|||
Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1 | [1] | |
Company |
University of Texas Southwestern Medical Center
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | B-cell receptor CD22 (CD22) | Target Info | Modulator | [2] |
B-lymphocyte surface antigen B4 (CD19) | Target Info | Modulator | [2] | |
KEGG Pathway | Cell adhesion molecules (CAMs) | |||
Hematopoietic cell lineage | ||||
B cell receptor signaling pathway | ||||
PI3K-Akt signaling pathway | ||||
Epstein-Barr virus infection | ||||
Primary immunodeficiency | ||||
NetPath Pathway | IL-7 Signaling Pathway | |||
Panther Pathway | B cell activation | |||
Pathway Interaction Database | BCR signaling pathway | |||
Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
PIP3 activates AKT signaling | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | ||||
WikiPathways | B Cell Receptor Signaling Pathway | |||
Human Complement System | ||||
Signaling by the B Cell Receptor (BCR) | ||||
PIP3 activates AKT signaling | ||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027936) | |||
REF 2 | A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.